bedaquiline + linezolid + sitafloxacin + pyrazinamide

This is a combination regimen consisting of four small-molecule antibiotics—bedaquiline, linezolid, sitafloxacin, and pyrazinamide—used for the treatment of tuberculosis (TB), particularly drug-resistant forms. - **Bedaquiline** is a diarylquinoline that inhibits mycobacterial ATP synthase, disrupting energy production in *Mycobacterium tuberculosis*. - **Linezolid** is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. - **Sitafloxacin** is a fluoroquinolone antibiotic that targets DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication. - **Pyrazinamide** is a prodrug converted to pyrazinoic acid in susceptible strains of *M. tuberculosis*, disrupting membrane transport and energy production. This combination aims to provide potent bactericidal activity against TB bacteria—including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains—by targeting multiple pathways critical for bacterial survival.